ESR1 and benign prostatic hyperplasia: In addition to the down-regulation of 5AR and AR, VA administration also suppressed the level of ERα compared to that of the BPH group, which may suggest another potential action mechanism of VA on BPH treatment besides the 5AR-AR axis.